Trial Profile
Phase II Trial of Natalizumab (Tysabri) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Sep 2020
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary) ; Methylprednisolone
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 08 Sep 2020 Primary endpoint (GVHD-free survival rate) has not been met.
- 08 Sep 2020 Status changed to discontinued.
- 08 Sep 2020 Results published in the Bone Marrow Transplantation.